125 related articles for article (PubMed ID: 1677643)
1. p185HER2 signal transduction in breast cancer cells.
Scott GK; Dodson JM; Montgomery PA; Johnson RM; Sarup JC; Wong WL; Ullrich A; Shepard HM; Benz CC
J Biol Chem; 1991 Aug; 266(22):14300-5. PubMed ID: 1677643
[TBL] [Abstract][Full Text] [Related]
2. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth.
Sarup JC; Johnson RM; King KL; Fendly BM; Lipari MT; Napier MA; Ullrich A; Shepard HM
Growth Regul; 1991 Jun; 1(2):72-82. PubMed ID: 1688187
[TBL] [Abstract][Full Text] [Related]
3. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu.
Benz CC; Scott GK; Sarup JC; Johnson RM; Tripathy D; Coronado E; Shepard HM; Osborne CK
Breast Cancer Res Treat; 1992; 24(2):85-95. PubMed ID: 8095168
[TBL] [Abstract][Full Text] [Related]
4. Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells.
Kumar R; Shepard HM; Mendelsohn J
Mol Cell Biol; 1991 Feb; 11(2):979-86. PubMed ID: 1671297
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine phosphatase inhibition permits analysis of signal transduction complexes in p185HER2/neu-overexpressing human tumor cells.
Jallal B; Schlessinger J; Ullrich A
J Biol Chem; 1992 Mar; 267(7):4357-63. PubMed ID: 1347042
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody.
Kern JA; Torney L; Weiner D; Gazdar A; Shepard HM; Fendly B
Am J Respir Cell Mol Biol; 1993 Oct; 9(4):448-54. PubMed ID: 8104437
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic.
Shepard HM; Lewis GD; Sarup JC; Fendly BM; Maneval D; Mordenti J; Figari I; Kotts CE; Palladino MA; Ullrich A
J Clin Immunol; 1991 May; 11(3):117-27. PubMed ID: 1679763
[TBL] [Abstract][Full Text] [Related]
8. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies.
Lewis GD; Figari I; Fendly B; Wong WL; Carter P; Gorman C; Shepard HM
Cancer Immunol Immunother; 1993 Sep; 37(4):255-63. PubMed ID: 8102322
[TBL] [Abstract][Full Text] [Related]
9. Reduced expression of c-erbB2 gene product in human mammary carcinoma SK-BR-3 cells treated with interferon-gamma and tumor necrosis factor-alpha.
Kumar R; Mendelsohn J
Anticancer Res; 1994; 14(3A):1001-8. PubMed ID: 7915505
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
[TBL] [Abstract][Full Text] [Related]
11. Growth inhibition of breast cancer cell lines by combinations of anti-P185HER2 monoclonal antibody and cytokines.
Kopreski MS; Lipton A; Harvey HA; Kumar R
Anticancer Res; 1996; 16(1):433-6. PubMed ID: 8615649
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma.
Peles E; Levy RB; Or E; Ullrich A; Yarden Y
EMBO J; 1991 Aug; 10(8):2077-86. PubMed ID: 1676673
[TBL] [Abstract][Full Text] [Related]
13. Antibody-induced activation of p185HER2 in the human lung adenocarcinoma cell line Calu-3 requires bivalency.
Srinivas U; Tagliabue E; Campiglio M; Ménard S; Colnaghi MI
Cancer Immunol Immunother; 1993 Jun; 36(6):397-402. PubMed ID: 8098992
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
15. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.
Arteaga CL; Winnier AR; Poirier MC; Lopez-Larraza DM; Shawver LK; Hurd SD; Stewart SJ
Cancer Res; 1994 Jul; 54(14):3758-65. PubMed ID: 7913407
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
17. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
Normanno N; Campiglio M; De LA; Somenzi G; Maiello M; Ciardiello F; Gianni L; Salomon DS; Menard S
Ann Oncol; 2002 Jan; 13(1):65-72. PubMed ID: 11863114
[TBL] [Abstract][Full Text] [Related]
18. Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells.
Sepp-Lorenzino L; Eberhard I; Ma Z; Cho C; Serve H; Liu F; Rosen N; Lupu R
Oncogene; 1996 Apr; 12(8):1679-87. PubMed ID: 8622888
[TBL] [Abstract][Full Text] [Related]
19. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
Ram TG; Ethier SP
Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells.
Golubovskaya V; Beviglia L; Xu LH; Earp HS; Craven R; Cance W
J Biol Chem; 2002 Oct; 277(41):38978-87. PubMed ID: 12167618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]